GlassScriptPhysician profile
Rick P Sessions
NPI 1780634949
$4,695.79
in general payments reported to CMS, 2019-2025
56 companies · $844 in 2025
The $844 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,650 · 2022: $790 · 2023: $713 · 2024: $699 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $514.00 | 2021-2022 | |
| Pfizer INC. | $368.00 | 2021-2025 | |
| Medtronic, INC. | $330.73 | 2021-2024 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $302.95 | 2021-2025 | |
| Incyte Corporation | $214.95 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Janssen Biotech, INC. | $189.61 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $170.66 | 2021-2025 | Ninlaro, Fruzaqla |
| Servier Pharmaceuticals LLC | $157.40 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $152.83 | 2021-2023 | Prolaris |
| Astellas Pharma US INC | $146.20 | 2021-2023 | Padcev |
| Merck Sharp & Dohme LLC | $139.89 | 2022-2025 | Keytruda, Lynparza |
| Abbvie INC. | $138.53 | 2021-2025 | |
| Seagen INC. | $129.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.10 | 2021-2024 | Enhertu |
| Novartis Pharmaceuticals Corporation | $111.06 | 2022-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $90.76 | 2022-2024 | Octagam Immune Globulin (Human) |
| Foundation Medicine, INC. | $74.94 | 2021 | |
| Alexion Pharmaceuticals, INC. | $70.04 | 2021-2023 | Ultomiris |
| Pharmaessentia USA Corporation | $67.95 | 2022-2025 | Besremi |
| Amgen INC. | $65.18 | 2022-2023 | Blincyto |
| Genentech USA, INC. | $64.99 | 2024-2025 | Polivy, Venclexta |
| Daiichi Sankyo INC. | $64.17 | 2021-2022 | |
| Genzyme Corporation | $62.71 | 2022-2025 | |
| Blue Earth Diagnostics | $60.06 | 2021-2025 | Posluma |
| Ipsen Biopharmaceuticals, INC | $59.71 | 2021-2023 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $59.65 | 2021-2024 | Jemperli, Zejula |
| Exelixis INC. | $58.13 | 2023-2025 | Cabometyx |
| Taiho Oncology, INC. | $48.23 | 2021-2023 | |
| Lilly USA, LLC | $45.41 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Agios Pharmaceuticals, INC. | $44.18 | 2021-2023 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $41.50 | 2022-2023 | Imbruvica |
| Axonics, INC. | $36.89 | 2023 | Axonics |
| Teleflex LLC | $35.85 | 2025 | Barrigel |
| Sumitomo Pharma America, INC. | $34.46 | 2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $33.84 | 2022-2025 | Clonoseq |
| Sobi, INC | $31.69 | 2025 | |
| Stemline Therapeutics INC. | $26.72 | 2024 | Orserdu |
| Coloplast Corp | $25.88 | 2025 | |
| Geron Corporation | $23.99 | 2024 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $22.12 | 2022 | |
| Antares Pharma, INC. | $19.93 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.53 | 2021 | |
| Eisai INC. | $19.51 | 2021 | |
| G1 Therapeutics, INC. | $18.88 | 2023 | Cosela |
| Eusa Pharma (US) LLC | $18.57 | 2021 | |
| Beone Medicines USA, INC. | $17.99 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $17.25 | 2025 | |
| Ge Healthcare | $16.28 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.16 | 2021 | |
| Puma Biotechnology, INC. | $15.69 | 2022 | |
| Novocure INC. | $15.60 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $15.17 | 2023 | Yonsa, Odomzo |
| Myovant Sciences INC. | $14.41 | 2021 | |
| Karyopharm Therapeutics INC. | $14.11 | 2021 | |
| Beigene USA, INC. | $13.48 | 2024 | Brukinsa |
| Blueprint Medicines Corporation | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Sessions listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.